Cargando…

The Parkinson’s Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures

There is an increasing need for improved endpoints to assess clinical trial effects in Parkinson’s disease. We propose the Parkinson’s Disease Comprehensive Response as a novel weighted composite endpoint integrating changes measured in three established Parkinson’s outcomes, including: OFF state Mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luz, Matthias, Whone, Alan, Bassani, Niccolò, Wyse, Richard K, Stebbins, Glenn T, Mohr, Erich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759656/ https://www.ncbi.nlm.nih.gov/pubmed/33392501 http://dx.doi.org/10.1093/braincomms/fcaa046

Ejemplares similares

Ventral Striatal Dopamine Synthesis Capacity Predicts Financial Extravagance in Parkinson’s Disease
por: Lawrence, Andrew D., et al.
Publicado: (2013)

Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study
por: Carroll, Camille B, et al.
Publicado: (2019)

Acceptability of an In-home Multimodal Sensor Platform for Parkinson Disease: Nonrandomized Qualitative Study
por: Morgan, Catherine, et al.
Publicado: (2022)

Are patients with Parkinson’s disease blind to blindsight?
por: Diederich, Nico J., et al.
Publicado: (2014)

The Association Between Frailty and Parkinson’s Disease in the ReSPOnD Trial
por: Smith, Natalie, et al.
Publicado: (2021)

Effects of dopamine on reinforcement learning and consolidation in Parkinson’s disease
por: Grogan, John P, et al.
Publicado: (2017)

Comparison of Test Your Memory and Montreal Cognitive Assessment Measures in Parkinson's Disease
por: Henderson, Emily J., et al.
Publicado: (2016)

Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease
por: Whone, Alan L., et al.
Publicado: (2019)

Multimodal Classification of Parkinson’s Disease in Home Environments with Resiliency to Missing Modalities
por: Heidarivincheh, Farnoosh, et al.
Publicado: (2021)

Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?
por: Tosin, Michelle H.S., et al.
Publicado: (2022)

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen
por: Henderson, Emily J, et al.
Publicado: (2013)

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease
por: Whone, Alan, et al.
Publicado: (2019)

An Automatic Gait Analysis Pipeline for Wearable Sensors: A Pilot Study in Parkinson’s Disease
por: Peraza, Luis R., et al.
Publicado: (2021)

Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis
por: Fundament, Tomasz, et al.
Publicado: (2016)

Automated Real-World Video Analysis of Sit-to-Stand Transitions Predicts Parkinson’s Disease Severity
por: Morgan, Catherine, et al.
Publicado: (2023)

Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes
por: Wang, Wenzhang, et al.
Publicado: (2015)

Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment
por: Morgan, Catherine, et al.
Publicado: (2020)

Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations
por: Kroonenberg, Pieter M, et al.
Publicado: (2006)

Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models
por: Luo, Sheng, et al.
Publicado: (2021)

Application of longitudinal item response theory models to modeling Parkinson’s disease progression
por: Zou, Haotian, et al.
Publicado: (2022)

Parkinson Matters
por: Darweesh, Sirwan K.L., et al.
Publicado: (2018)

Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial
por: Stevens, Kara N., et al.
Publicado: (2022)

Referring Parkinson’s disease patients for deep brain stimulation: a RAND/UCLA appropriateness study
por: Moro, Elena, et al.
Publicado: (2015)

Linear growth and mid-childhood cognitive outcomes in three birth cohorts of term-born children: an approach to integrating three growth models to explore critical windows
por: Leung, Michael, et al.
Publicado: (2020)

Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
por: Stott, Simon R. W., et al.
Publicado: (2021)

A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson’s disease
por: Lo, Christine, et al.
Publicado: (2022)

The implementation and impacts of national standards for comprehensive care in acute care hospitals: An integrative review
por: Xiong, Beibei, et al.
Publicado: (2023)

Understanding how people with Parkinson's disease turn in gait from a real-world in-home dataset
por: Morgan, Catherine, et al.
Publicado: (2022)

Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress
por: Carroll, Camille B., et al.
Publicado: (2017)

Inaccurate self-report of olfactory dysfunction in REM Sleep Behaviour Disorder and implications for prognosis
por: Roguski, Amber, et al.
Publicado: (2022)

Standardized Method for High-throughput Sterilization of Arabidopsis Seeds
por: Lindsey, Benson E., et al.
Publicado: (2017)

Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
por: Neumann, S., et al.
Publicado: (2021)

How personal and standardized coordination impact implementation of integrated care
por: Benzer, Justin K., et al.
Publicado: (2015)

Assessing Agreement between miRNA Microarray Platforms
por: Bassani, Niccolò P., et al.
Publicado: (2014)

Predictive language comprehension in Parkinson’s disease
por: Aveni, Katharine, et al.
Publicado: (2023)

Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
por: Tosin, Michelle H. S., et al.
Publicado: (2022)

Sustainable Cement Composite Integrating Waste Cellulose Fibre: A Comprehensive Review
por: Fernando, Sarah, et al.
Publicado: (2023)

GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
por: Barker, Roger A., et al.
Publicado: (2020)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
por: McFarthing, Kevin, et al.
Publicado: (2020)

Anatomical plantar pressure masking and foot models: potential for integration with marker position systems
por: Giacomozzi, Claudia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mckeu4h202ln09sttec9hvvd9a